Project description
Human genome pathogenic micropeptides
Recent studies have discovered a striking number of regions of the genome that are capable of being transcribed and translated into short polypeptides. These micropeptides comprise less than 100 amino acids, and more than 160 000 different micropeptides have been cataloged within human tissues so far. The current hypothesis is that these genome products might participate in numerous physiological processes, yet the function of only a few micropeptides has been clarified. The EU-funded GENOMEPEP project aims to identify particular micropeptides participating in the pathogenesis of cardiovascular diseases by analysing the genetic variation within the micropeptidome-encoding genome in correlation to existing common cardiovascular phenotypes in the population.
Objective
The human genome is over 3 billion nucleotides long, yet only 1,5% of it codes for proteins. In recent years, a striking number of regions of the genome have been discovered to be capable of being transcribed and translated into short polypeptides. These micropeptides comprise of less than 100 amino acids and to date, more than 160 000 different micropeptides have been catalogued within human tissues. These protein products are hypothesized to participate in numerous molecular, cellular and physiological processes, yet the function of but a few micropeptides has been identified. Subsequently, due to its largely unknown functionality, the micropeptidome is commonly overlooked during genomic studies.
Due to increasing life expectancy and detrimental lifestyle habits, the European population can be considered to be a high-risk population for cardiovascular diseases, which cause millions of deaths per annum, while taking a tremendous financial toll on the regional economy. GENOMEPEP aims to pinpoint novel micropeptides participating in the pathogenesis of cardiovascular diseases by investigating the genetic variation within the micropeptidome-encoding genome in correlation to existing common cardiovascular phenotypes in population. This will be achieved by establishing a computational analysis pipeline based on biometric, genotype and health records data available within the Estonian and Finnish biobanks. The identification of novel pathogenic genes and the development of guidelines to investigate the micropeptidome would assist in the advancement of research, diagnostic medicine and pharmacology both in public and private sectors.
The results of GENOMEPEP will address the CVD research aspect highlighted in “Societal Challenge 1” work program of Horizon 2020, as well as improve other research priorities set by Horizon 2020, e.g. the progression of personalized medicine and support the decrease of economic burden by healthcare.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine cardiology cardiovascular diseases
- medical and health sciences health sciences personalized medicine
- natural sciences chemical sciences organic chemistry amines
- natural sciences biological sciences genetics genomes
- medical and health sciences basic medicine pharmacology and pharmacy
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2019
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
51005 TARTU
Estonia
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.